利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.018 秒)

    GLP-2 formulations
    21.
    发明授权
    GLP-2 formulations 有权
    GLP-2制剂

    公开(公告)号：US07056886B2

    公开(公告)日：2006-06-06

    申请号：US09750022

    申请日：2000-12-29

    申请人： Indu J. Isaacs

    发明人： Indu J. Isaacs

    IPC分类号： A61K38/00 ,  A61K38/26 ,  C07K14/00

    CPC分类号： A61K47/26 ,  A61K9/0019 ,  A61K38/26 ,  A61K47/02 ,  A61K47/18

    摘要： The invention is directed to formulations of GLP-2 peptides and analogs thereof exhibiting superior stability following storage and/or exposure to elevated temperatures. The GLP-2 compositions comprise a GLP-2 peptide or an analog thereof, a phosphate buffer, L-histidine, and mannitol.

    摘要翻译： 本发明涉及GLP-2肽及其类似物的制剂，其在储存和/或暴露于升高的温度后表现出优异的稳定性。 GLP-2组合物包含GLP-2肽或其类似物，磷酸盐缓冲液，L-组氨酸和甘露糖醇。

    Production of glucagon like peptide 2 and analogs
    22.
    发明申请
    Production of glucagon like peptide 2 and analogs 失效
    产生胰高血糖素样肽2和类似物

    公开(公告)号：US20050164930A1

    公开(公告)日：2005-07-28

    申请号：US10993127

    申请日：2004-11-22

    申请人： Ken Sasaki ,  Vanessa Jane Williamson ,  Alberto de Araujo ,  Ewa Walczyk

    发明人： Ken Sasaki ,  Vanessa Jane Williamson ,  Alberto de Araujo ,  Ewa Walczyk

    IPC分类号： C07K14/605 ,  C12N1/21 ,  C12N15/74

    CPC分类号： C07K14/605 ,  C07K2319/00

    摘要： GLP-2 peptides and analogs thereof are produced in high yield and with desired, authentic termini by isolation from a GLP-2 peptide multimer in which at least two units of GLP-2 peptide are coupled through a linker that presents an N-terminal acid cleavage site and a C-terminal enzyme cleavage site. In a specific embodiment, [Gly2]hGLP-2 is produced from a multimeric precursor comprising 2-30 units thereof.

    摘要翻译： 通过从其中至少两个单元的GLP-2肽通过呈现N末端酸的连接体偶联的GLP-2肽多聚体分离，以高产率和期望的真实末端产生GLP-2肽及其类似物 切割位点和C末端酶切割位点。 在一个具体实施方案中，由包含其2-30单位的多聚前体产生[Gly 2] hGLP-2。

    Production of human parathyroid hormone from microorganisms
    24.
    发明申请
    Production of human parathyroid hormone from microorganisms 审中-公开
    从微生物生产人甲状旁腺激素

    公开(公告)号：US20040005668A1

    公开(公告)日：2004-01-08

    申请号：US10359091

    申请日：2003-02-06

    申请人： NPS Allelix Corp.

    发明人： Kaare M. Gautvik ,  Peter Alestrom ,  Tordis Beate Oyen ,  Odd Stokke Gabrielsen

    IPC分类号： C12P021/02 ,  C12N001/18 ,  C07K014/635 ,  C07H021/04 ,  C12N015/74

    CPC分类号： C07K14/635 ,  A61K38/00 ,  C07K2319/02 ,  C12N15/64 ,  C12N15/66 ,  C12N15/67 ,  C12N15/70 ,  C12N15/81

    摘要： The invention provides recombinant plasmids containing in DNA sequences coding for human preproparathyroid hormone. The invention further provides microorganisms, for example E. coli, transformed by these plasmids. The invention also provides a plasmid for insertion into yeast and a transformed yeast in which the plasmid contains DNA coding for parathyroid hormone. Parathyroid hormone is then secreted by the transformed yeast. Further the invention provides alternate polypeptides having parathyroid hormone activity, including PTH analogs, fragments and extensions, and provides alternate leader sequences and secretion signal sequences which can be used in the present invention. Finally, there are provided methods for purification of the secreted PTH hormone and/or derivatives.

    摘要翻译： 本发明提供含有编码人前甲状腺激素的DNA序列的重组质粒。 本发明还提供了由这些质粒转化的微生物，例如大肠杆菌。 本发明还提供了用于插入酵母的质粒和其中质粒含有编码甲状旁腺激素的DNA的转化酵母。 甲状旁腺激素然后被转化的酵母分泌。 此外，本发明提供了具有甲状旁腺激素活性的替代多肽，包括PTH类似物，片段和延伸，并提供可用于本发明的替代前导序列和分泌信号序列。 最后，提供了分泌的PTH激素和/或衍生物的纯化方法。

    Azaindoles having serotonin receptor affinity
    29.
    发明申请
    Azaindoles having serotonin receptor affinity 失效
    阿魏醇具有5-羟色胺受体亲和力

    公开(公告)号：US20050239788A1

    公开(公告)日：2005-10-27

    申请号：US11165122

    申请日：2005-06-24

    申请人： Louise Edwards ,  Abdelmalik Slassi ,  Ashok Tehim ,  Tao Xin

    发明人： Louise Edwards ,  Abdelmalik Slassi ,  Ashok Tehim ,  Tao Xin

    IPC分类号： A61K31/498 ,  A61P25/18 ,  A61P25/24 ,  C07D471/04 ,  C07D487/04 ,  C07D519/00

    CPC分类号： C07D471/04 ,  C07D519/00

    摘要： Described herein are compounds with affinity for the 5-HT6 receptor, which have the general formula I: wherein: R represents a group of Formula II or Formula III; one of A, B D or E is a N atom, the remainder being CH groups; R1 is selected from the group consisting of SO2Ar, C(O)Ar, CH2Ar and Ar; R2, R3 and R4 are independently selected from the group consisting of H and alkyl;  represents a single or double bond, with the proviso that there is only one double bond in the ring at a time; n is an integer of from 1-3; Z is selected from the group consisting of C, CH and N, provided that when  is a double bond, Z is C and when  is a single bond, Z is selected from CH and N; Ar is an optionally substituted aryl group; with the proviso that when R is a group of Formula II, R1 is SO2Ar. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT6 receptor is implicated, such as schizophrenia.

    摘要翻译： 本文描述的是具有对具有通式I的5-HT 6受体具有亲和性的化合物：其中：R代表式II或式III的基团; A，B D或E之一为N原子，其余为CH基团; R 1选自SO 2 Ar，C（O）Ar，CH 2 Ar和Ar; R 2，R 3和R 4独立地选自H和烷基; 代表单键或双键，条件是每次只有一个双键; n为1-3的整数; Z选自C，CH和N，条件是当是双键时，Z是C，当是单键时，Z选自CH和N; Ar是任选取代的芳基; 条件是当R是式II的基团时，R 1是SO 2 Ar。 还描述了这些化合物作为药物用于治疗其中涉及5-HT 6受体的抑制的适应症的用途，例如精神分裂症。

    Modulatory proteins of human CNS receptors
    30.
    发明申请
    Modulatory proteins of human CNS receptors 审中-公开

    公开(公告)号：US20030087371A1

    公开(公告)日：2003-05-08

    申请号：US10146806

    申请日：2002-08-19

    申请人： NPS ALLELIX CORP.

    发明人： Robert L. Foldes ,  Sally-Lin Adams ,  Rajender Kamboj

    IPC分类号： C12P021/02 ,  C12N005/06 ,  C07K014/705 ,  C07H021/04

    CPC分类号： C07K14/705 ,  C07K14/70571 ,  G01N33/567 ,  G01N33/68

    摘要： Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. This neurotransmission has been found to be modulated by certain modulatory proteins. DNA coding for a family of such modulatory proteins has now been isolated and the modulatory proteins have been characterized. Herein described are recombinant cell lines which produce these modulatory proteins as heterologous membrane-bound products. Also described are related aspects of the invention, which are of commercial significance, including the use of cell lines which express the modulatory proteins either homomerically, or heteromerically in a complex with an NMDA receptor, as a tool for discovery of compounds which affect the function of the modulatory proteins.